Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 3/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8796942 | 0.81 | FBP1 (0.57) | SMN1; SMN2ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL11188489 | 0.80 | HPGD (0.60) | HSD17B10SMN1; SMN2ALDH1A1MAPTPTPRC | |
| SCHEMBL9577390 | 0.75 | KDM4E (0.46) | SMN1; SMN2L3MBTL1FBP1PDK1PDPK1 | |
| SCHEMBL8797344 | 0.74 | HTR7 (0.46) | SMN1; SMN2MAPTHTR7FBP1PDK1 | |
| SCHEMBL3263155 | 0.74 | LMNA (0.72) | SMN1; SMN2ALDH1A1MAPTPKMLMNA | |
| SCHEMBL21751245 | 0.73 | CTSA (0.46) | DCUN1D1 | |
| SCHEMBL11823301 | 0.73 | FBP1 (0.61) | HSD17B10SMN1; SMN2ALDH1A1HTR7FBP1 | |
| SCHEMBL2982080 | 0.72 | FBP1 (0.52) | SMN1; SMN2HTR7FBP1PDK1PDPK1 | |
| SCHEMBL4159772 | 0.72 | HTR7 (0.44) | SMN1; SMN2HTR7FBP1PDK1 | |
| SCHEMBL1029180 | 0.71 | HSD17B10 (1.00) | HSD17B10SMN1; SMN2ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | claimed |
| EP-3365819-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | Mangosuthu University Of Technology (ZA) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070719-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2017-04-27 | — | — | WO | claimed |
| EP-0380305-B1 | ORI-INHIBITED AND DEPOSIT-RESISTANT MOTOR FUEL COMPOSITION | TEXACO DEVELOPMENT CORPORATION (US) | 1992-06-17 | — | — | EP | claimed |
| EP-0315293-B1 | OXIDATION AND CORROSION RESISTANT DIESEL ENGINE LUBRICANT | TEXACO DEVELOPMENT CORPORATION (US) | 1992-04-08 | — | — | EP | claimed |
| US-4981493-A | OCTANE REQUIREMENT INCREASE, FUEL ADDITIVES, MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | TEXACO INC. (US) | 1991-01-01 | — | — | US | claimed |
| US-4981604-A | POLYOXYALKYLENEDIAMINE, ANHYDRIDE, HETEROCYCLIC AZOLE | TEXACO INC. (US) | 1991-01-01 | — | — | US | claimed |
| EP-0380305-A1 | Ori-inhibited and deposit-resistant motor fuel composition | TEXACO DEVELOPMENT CORPORATION (US) | 1990-08-01 | — | — | EP | claimed |
| US-4865622-A | OCTANE REQUIREMENT INCREASE, DIBASIC ACID ANHYDRIDE-POLYOXYALKYLENE DIAMINE-HETEROCYCLIC AZOLE REACTION PRODUCT | TEXACO INC. (US) | 1989-09-12 | — | — | US | claimed |
| EP-0315293-A2 | Oxidation and corrosion resistant diesel engine lubricant | TEXACO DEVELOPMENT CORPORATION (US) | 1989-05-10 | — | — | EP | claimed |
| US-4808335-A | ANTIOXIDANT IS REACTION PRODUCT OF N-ACYLSARCOSINE DERIVATIVE AND HETEROCYCLIC AZOLES | TEXACO INC. (US) | 1989-02-28 | — | — | US | claimed |
| US-4758363-A | Oxidation and corrosion resistant diesel engine lubricant | TEXACO INC. (US) | 1988-07-19 | — | — | US | claimed |
| EP-3365330-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3365819-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| US-4808335-A | ANTIOXIDANT IS REACTION PRODUCT OF N-ACYLSARCOSINE DERIVATIVE AND HETEROCYCLIC AZOLES | TEXACO INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4758363-A | Oxidation and corrosion resistant diesel engine lubricant | TEXACO INC. (US) | 1988-07-19 | — | — | US | disclosed |
| US-4705642-A | Haze, oxidation, and corrosion resistant diesel engine lubricant | TEXACO INC. (US) | 1987-11-10 | — | — | US | disclosed |
| US-4064135-A | Certain thiazole-5-carboxamide compounds | SYNTEX (U.S.A.) INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | HSD17B10 57/4885SMN1; SMN2 4592/4885ALDH1A1 103/4885 |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | HSD17B10 101/4885SMN1; SMN2 4692/4885ALDH1A1 119/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | HSD17B10 101/4885SMN1; SMN2 4692/4885ALDH1A1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.